Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2008

01.01.2008 | Original article

Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas

verfasst von: A. Smits, E. Westerberg, D. Ribom

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of 11C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system.

Methods

In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0–2 unfavourable factors) and 26 cases as high-risk patients (3–5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups.

Results

In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours.

Conclusions

Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.
Literatur
1.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215–25.PubMed
2.
Davis FG, Preston-Martin S. Epidemiology. Incidence and survival. In: Bigner DD, McLendon RE, Bruner JM, editors. Russell & Rubinstein’s pathology of tumors of the nervous system. London: Arnold; 1998. p. 135–48.
3.
Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005;109:93–8.PubMedCrossRef
4.
Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001;95:735–45.PubMed
5.
Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996;36:549–56.PubMed
6.
Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002;52:316–24.PubMed
7.
Shaw E, Arusell R, Scheithauer B, O´Fallon J, O´Neill B, Dinapoli R, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002;20:2267–76.PubMedCrossRef
8.
Pignatti F, van den Bent M, Curran D, Debruyne C., Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20:2076–84.PubMedCrossRef
9.
Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 2006;104:238–53.PubMedCrossRef
10.
Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316–22.PubMed
11.
De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001;95:746–50.PubMedCrossRef
12.
Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B, et al. Positron emission tomography 11C-methionine and survival in patients with low-grade gliomas. Cancer 2001;92:1541–9.PubMedCrossRef
13.
Kaschten B, Stevenaert A, Sadzot B, Deprez M, Dequeldre C, Del Fiore G, et al. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med 1998;39:778–85.PubMed
14.
Ribom D, Engler H, Blomquist E, Smits A. Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med 2002;29:632–40.CrossRef
15.
Bergstrom M, Lundqvist H, Ericson K, Lilja A, Johnstrom P, Langstrom B, et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987;28:225–9.PubMedCrossRef
16.
Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994;74:1784–91.PubMedCrossRef
17.
Armstrong CL, Hunter JV, Ledakis GE, Cohen B, Tallent EM, Goldstein BH, et al. Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology 2002;59:40–8.PubMed
18.
Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 2000;54:1442–8.PubMed
19.
Surma-aho O, Niemela M, Vilkki J, Kouri M, Brander A, Salonen O, et al. Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001;56:1285–90.PubMed
20.
Postma TJ, Klein M, Verstappen CC, Bromberg JE, Swennen M, Langendijk JA, et al. Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology 2002;59:121–3.PubMed
21.
Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO. Prognostic factors for low-grade gliomas. Semin Oncol 2003;30:23–8.PubMedCrossRef
22.
Daumas-Duport C. Histological grading of gliomas. Curr Opin Neurol Neurosurg 1992;5:924–31.PubMed
23.
Bell D, Grant R, Collie D, Walker M, Whittle IR. How well do radiologists diagnose intracerebral tumour histology on CT? Findings from a prospective multicentre study. Br J Neurosurg 2002;16:573–7.PubMed
24.
Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999;45:923–9.PubMed
25.
van den Bent MJ, Stupp R, Brandes AA, Lacombe D. Current and future trials of the EORTC brain tumor group. Onkologie 2004;27:246–50.PubMedCrossRef
Metadaten
Titel
Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas
verfasst von
A. Smits
E. Westerberg
D. Ribom
Publikationsdatum
01.01.2008
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2008
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-007-0531-1

Weitere Artikel der Ausgabe 1/2008

European Journal of Nuclear Medicine and Molecular Imaging 1/2008 Zur Ausgabe

Original article

The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer

Original article

In vivo amyloid imaging with PET in frontotemporal dementia

Original article

Comparative analysis of MR imaging, Ictal SPECT and EEG in temporal lobe epilepsy: a prospective IAEA multi-center study

Focus on

Labeling peptides with PET radiometals: Vulcan’s forge

Original article

Prognostic value of 99mTc-HYNIC Annexin-V imaging in squamous cell carcinoma of the head and neck

Image of the month

Intestinal accumulation of 99mTc-MDP in a patient with protein-losing enteropathy